[{"orgOrder":0,"company":"Sesen Bio","sponsor":"Qilu Pharmaceutical","pharmaFlowCategory":"D","amount":"$35.0 million","upfrontCash":"$12.0 million","newsHeadline":"Sesen Bio Signs Exclusive License Agreement with Qilu Pharmaceutical for the Development and Commercialization of Vicineum\u2122 in Greater China","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Agreement","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0.040000000000000001,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Sesen Bio \/ Qilu Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Qilu Pharmaceutical"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Cardinal Health","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio Ink Exclusive Agreement With Cardinal Health for Third-Party Logistics and Specialty Pharma Distribution Services for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Collaboration","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesen Bio \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Sesen Bio"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces Successful Pre-Submission Meeting with the European Medicines Agency for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2020","year":"2020","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Submits Completed Biologics License Application to the FDA for Vicineum\u2122 and Has Requested Priority Review","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2020","year":"2020","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Viventia Bio","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Viventia Bio","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Viventia Bio"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Strengthens Leadership Team as the Company Approaches the Potential Approval and Launch of Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Receives Complete Response Letter from FDA for Vicineum\u2122 (oportuzumab monatox-qqrs)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Approaches the Potential Approval and Commercial Launch of Vicineum\u2122","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Expands CMC and Clinical Teams","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Not Applicable","leadProduct":"Oportuzumab Monatox-qqrs","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravesical","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sesen Bio Announces Strategic Decision to Pause Clinical Development of Vicineum\u2122 in the US","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","year":"2022","type":"Not Applicable","leadProduct":"Vicineum","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sesen Bio \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio and Carisma Therapeutics Announce Merger Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","year":"2022","type":"Merger","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"Sesen Bio \/ Sesen Bio","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio \/ Sesen Bio"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"Undisclosed","newsHeadline":"Sesen Bio and Carisma Therapeutics Announce Substantial Increase to Expected Special Cash Dividend in Connection with Pending Merger","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","year":"2022","type":"Merger","leadProduct":"Oportuzumab Monatox","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III","graph3":"Sesen Bio","amount2":0.029999999999999999,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase III","highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Sesen Bio \/ Sesen Bio","highestDevelopmentStatusID":"10","companyTruncated":"Sesen Bio \/ Sesen Bio"},{"orgOrder":0,"company":"Sesen Bio","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Carisma Therapeutics Closes Merger with Sesen Bio","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","year":"2023","type":"Merger","leadProduct":"CT-0508","moa":"","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I","graph3":"Sesen Bio","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase I","highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sesen Bio \/ Carisma Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sesen Bio \/ Carisma Therapeutics"}]
Find Clinical Drug Pipeline Developments & Deals by Sesen Bio
Details :
The combined company will develop Carisma's lead candidate CT-0508, a CAR-M cell therapy and will also accelerate the growth of company's platform and pipeline within and outside of oncology.
Details :
Vicineum (oportuzumab monatox) is an investigational locally administered recombinant fusion protein that targets epithelial cell adhesion molecule antigens on the surface of tumor cells to deliver Pseudomonas Exotoxin A.
Details :
The first clinical application of this technology is CT-0508, a CAR-M cell therapy currently being evaluated by Carisma in a Phase 1 multi-center clinical trial with a lead target indication of advanced HER2+ solid tumors.
Details :
VB4-845 (vicineum), a locally administered fusion protein for treatment of NMIBC, is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule antigens on surface of tumor cells to deliver a potent protein payload, Pseudomo...
Details :
Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Details :
Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A.
Details :
Vicineum is comprised of a recombinant fusion protein that targets EpCAM antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. It is currently under Priority Review with the FDA with a target PDUFA date of Au...
Details :
Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached to the antibody binding fragment until it is internalized by the cancer cell.
Details :
Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC).
Details :
Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). The BLA is supported by strong Phase 3 VISTA trial data and positive analy...
Market Place
Reset All
